Modern Health Science

Cross-Cultural Dietary Integration and Health Promotion: The Application and Potential of Chinese-Western Fusion Cuisine in Modern Health Science

2024-12-09T22:13:08+08:00

The fusion of Chinese and Western culinary traditions has evolved into a unique gastronomic phenomenon that bridges cultural boundaries while promoting health. This paper explores the intersection of Chinese-Western fusion cuisine and modern health science, analyzing its historical development, global influence, and contributions to healthy eating. By merging diverse ingredients, techniques, and health-focused innovations, fusion cuisine achieves both gastronomic satisfaction and nutritional balance. Utilizing systematic sample analysis, nutritional assessments, and case studies, this research highlights the potential of fusion cuisine in preventing chronic diseases, enhancing immunity, and fostering cultural appreciation. The findings underscore the pivotal role of fusion cuisine in advancing global dietary diversity and promoting sustainable, health-conscious food practices. Future directions are proposed for research and global promotion to unlock the full potential of this culinary innovation.

Comparison of in Vitro Proliferation and Antioxidant Activity Between Ginseng-Derived Exosome-Like Nanoparticles and Ginseng Original Liquid

2024-12-12T20:18:13+08:00

To compare the proliferation and antioxidant activity of Ginseng-derived exosome-like nanoparticles (GELNs) and Ginseng extracts (GEXs) in vitro. GEXs were prepared from natural plant ginseng, and GELNs were extracted by ultracentrifugation combined with sucrose density gradient centrifugation. The CCK-8 method was used to compare the effects of GELNs and GEXs on the proliferation of skin cells. The scratch test was used to compare the effects of GELNs and GEXs on the migration ability of skin cells, and then to verify the ability of GELNs and GEXs to promote proliferation, the antioxidant activity of GELNs and GEXs was compared by OH + DPPH + ABTS + FRAP method. The results showed that although GELNs and GEXs could promote the proliferation of human keratinocytes cells (HaCaT) at a certain concentration, GELNs not only showed better ability to promote the proliferation of skin cells, but also showed good biosafety. In addition, under the same protein concentration, GELNs showed stronger ability to scavenge OH, DPPH, ABTS free radicals and reduce iron ions than GEXs, that is, GELNs had relatively stronger antioxidant activity. The GELNs obtained by purification technology potentially improved the bioavailability and biosafety of ginseng, in order to provide a theoretical basis for its in-depth study as a natural antioxidant.

Principles of Standardized Diagnosis and Treatment of Immune Checkpoint Inhibitors (ICIs) and Analysis of Legal Liability for Treatment-Related Tumor Hyperprogression (HPD) Under Chinese Law

2024-12-15T13:13:43+08:00

Immunotherapy, led by immune checkpoint inhibitors, has reshaped the landscape of tumor treatment, achieving long-acting drug responses in some patients with advanced malignancies, but not all patients can benefit from immunotherapy. In addition to primary drug-resistant patients, we cannot ignore hyperprogressive patients whose disease is accelerated instead after the use of immune checkpoint inhibitors, which are rare but often have a very poor prognosis and are prone to disputes. The mechanism of hyperprogression is still unknown, but not unknown, and some genetic mutations and biomarkers have been shown to be associated with a higher risk of hyperprogression. Clinicians should stratify patients with reference to markers and risk mutations to screen effective patients and inform them of the corresponding risks of immune checkpoint inhibitor therapy to ensure that patients make a fully informed choice of immunotherapy. Comply with evidence-based medical guidelines, standardize the use of medication, and timely monitor and intervene in related adverse events and hyperprogression. Under Chinese law, violation of the principles of diagnosis and treatment is subject to liability, except for those caused by the patient himself, such as backline treatment and sympathetic drug administration.